• PDF / 170,567 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 70 Downloads / 221 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: 6 case reports In a retrospective analysis of the information received at the Russian Federal Database of Spontaneous Reports Regarding Adverse Reactions conducted between from 1 January 2015 and 31 December 2017, 6 patients including two female patients aged 12–38 years [not all ages and sexes not stated] were described who developed anaemia, thrombocytopenia, leukopenia, swelling of the right leg, bluish skin coloration of two fingers, thrombosis, injection site pain, injection site infiltration, decreased haemoglobin level, leukocyte count and thrombocyte count or elevated levels of AST and ALT during treatment with interferon-beta-1a or interferon-beta-1b for multiple sclerosis [routes and dosages not stated; not all duration to treatments to reactions onset and outcomes stated]. Patient 1: The patient had been receiving interferon beta-1b. After 1 year of therapy, laboratory tests revealed decreased hemoglobin level, WBC count and thrombocyte count against the background of the therapy. Therefore, interferon-beta-1b drug was discontinued resulting in improved clinical condition. Patient 2: The patient had been receiving interferon beta-1b. After 4.5 years of therapy, the patient developed fever. Laboratory tests revealed anaemia, thrombocytopenia and leucopenia. Under the guidance of physician, the dose of interferon beta-1b was decreased to 4 000 000IU for one month along with addition of unspecified pharmacotherapy and diet plan. However, the patient’s condition remained unchanged. Patient 3: The 31-year-old patient had been receiving interferon beta-1b. Subsequently, laboratory tests revealed an elevated levels of AST and ALT while decreased thrombocyte count and haemoglobin level against the background of therapy. Patient 4: The 38-year-old woman had been receiving interferon-beta-1b. After 4 years of therapy, she developed thrombocytopenia and leucopenia against the background of the therapy. Therefore, her interferon-beta-1b was suspended for two months; however, her condition remained unchanged. Patient 5: The patient had been receiving interferon beta-1b. Subsequently, the patient developed swelling of the right leg and the color of the skin of two fingers acquired a bluish tint. Thrombosis was diagnosed against the background of the therapy. The patient was admitted to the surgical department. However, the patient’s condition remained unchanged. Patient 6: The 12-year-old girl had been receiving interferon beta-1a. Subsequently, she developed thrombocytopenia and injection site pain and infiltration. Zatolochina KE, et al. Interferon beta: Analysis of information on adverse reactions and evaluation of possibility of signal identification. [Russian]. Safety and Risk of 803520275 Pharmacotherapy 7: 84-92, No. 2, 2019. Available from: URL: http://doi.org/10.30895/2312-7821-2019-7-2-84-92

0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 12 Dec 2020 No. 1834